US regulatory status: approved.
pharma · Asthma · Type 2 Diabetes
AstraZeneca
AstraZeneca drug portfolio — 77 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB HQ
79,242 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 129
- Drugs
- 77
- Patents
- 25
AstraZeneca pipeline
Portfolio lens on 77 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
AstraZeneca drug portfolio — 77 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
acalabrutinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
-
US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
-
aclidinium
Respiratory system (R03)Respiratory system (R03) compound in AstraZeneca's portfolio. Mechanism: Muscarinic acetylcholine receptor M3 antagonist.
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
aclidinium bromide
Respiratory system (R03)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M3.
- Target
- Muscarinic acetylcholine receptor M3
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
anifrolumab
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in AstraZeneca's portfolio. Molecular target: Interferon alpha/beta receptor 1.
- Target
- Interferon alpha/beta receptor 1
- Mechanism
- Interferon-alpha/beta receptor alpha chain antagonist
-
US regulatory status: approved.
-
benralizumab
Respiratory system (R03)US regulatory status: approved. Molecular target: Interleukin-5 receptor subunit alpha.
- Target
- Interleukin-5 receptor subunit alpha
- Mechanism
- Interleukin-5 receptor subunit alpha inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records. Mechanism: Beta-1 adrenergic receptor antagonist.
- Mechanism
- Beta-1 adrenergic receptor antagonist
-
budesonide
Alimentary tract and metabolism (A07)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to AstraZeneca in public FDA and regional records. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
capivasertib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Serine/threonine-protein kinase AKT.
- Target
- Serine/threonine-protein kinase AKT
- Mechanism
- Serine/threonine-protein kinase AKT inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
cediranib maleate
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in AstraZeneca's portfolio.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
dapagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
durvalumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
US regulatory status: approved. Molecular target: Interferon gamma.
- Target
- Interferon gamma
- Mechanism
- Interferon gamma inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
exenatide
Alimentary tract and metabolism (A10)Alimentary tract and metabolism (A10) compound in AstraZeneca's portfolio. Molecular target: Glucagon-like peptide 1 receptor.
- Target
- Glucagon-like peptide 1 receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
formoterol
Respiratory system (R03)Respiratory system (R03) compound in AstraZeneca's portfolio. Mechanism: Beta-2 adrenergic receptor agonist.
- Mechanism
- Beta-2 adrenergic receptor agonist
-
fostamatinib
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in AstraZeneca's portfolio. Molecular target: Tyrosine-protein kinase SYK.
- Target
- Tyrosine-protein kinase SYK
- Mechanism
- Tyrosine-protein kinase SYK inhibitor
-
gefitinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
lamivudine
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records. Mechanism: Mitochondrial complex I (NADH dehydrogenase) inhibitor.
- Mechanism
- Mitochondrial complex I (NADH dehydrogenase) inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
olaparib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: PARP 1, 2 and 3.
- Target
- PARP 1, 2 and 3
- Mechanism
- PARP 1, 2 and 3 inhibitor
-
osimertinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in AstraZeneca's portfolio. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Copper.
- Target
- Copper
- Mechanism
- Copper chelating agent
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records. Mechanism: Serotonin 2c (5-HT2c) receptor antagonist.
- Mechanism
- Serotonin 2c (5-HT2c) receptor antagonist
-
US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
roflumilast
Respiratory system (R03)US regulatory status: approved. Molecular target: Phosphodiesterase 4.
- Target
- Phosphodiesterase 4
- Mechanism
- Phosphodiesterase 4 inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
roxadustat
Blood and blood forming organs (B03)Blood and blood forming organs (B03) compound in AstraZeneca's portfolio. Molecular target: Hypoxia-inducible factor prolyl hydroxylase.
- Target
- Hypoxia-inducible factor prolyl hydroxylase
- Mechanism
- Hypoxia-inducible factor prolyl hydroxylase inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
saxagliptin
Alimentary tract and metabolism (A10)US regulatory status: approved.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Dipeptidyl peptidase 4.
- Target
- Dipeptidyl peptidase 4
- Mechanism
- Dipeptidyl peptidase IV inhibitor
-
sodium zirconium cyclosilicate
Various (V03)US regulatory status: approved. Molecular target: Potassium.
- Target
- Potassium
- Mechanism
- Potassium chelating agent
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records. Mechanism: Beta-2 adrenergic receptor agonist.
- Mechanism
- Beta-2 adrenergic receptor agonist
-
tezepelumab
Respiratory system (R03)Respiratory system (R03) compound in AstraZeneca's portfolio. Molecular target: Thymic stromal lymphopoietin.
- Target
- Thymic stromal lymphopoietin
- Mechanism
- Thymic stromal lymphopoietin inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
ticagrelor
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: P2Y purinoceptor 12.
- Target
- P2Y purinoceptor 12
- Mechanism
- Purinergic receptor P2Y12 negative allosteric modulator
-
tobramycin
Antiinfectives for systemic use (J01)US regulatory status: approved. Molecular target: 70S ribosome.
- Target
- 70S ribosome
- Mechanism
- 70S ribosome inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
trastuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.
- Target
- Receptor tyrosine-protein kinase erbB-2
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor
-
trastuzumab deruxtecan
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in AstraZeneca's portfolio. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I inhibitor
-
tremelimumab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in AstraZeneca's portfolio. Molecular target: Cytotoxic T-lymphocyte protein 4.
- Target
- Cytotoxic T-lymphocyte protein 4
- Mechanism
- Cytotoxic T-lymphocyte protein 4 inhibitor